Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs
Authors:
- Jun-Ichi EikiJEJun-Ichi Eiki
- Yasufumi NagataYNYasufumi Nagata
- Mayumi FutamuraMFMayumi Futamura
- Kaori Sasaki-YamamotoKSKaori Sasaki-Yamamoto
- Tomoharu IinoTITomoharu Iino
- Teruyuki NishimuraTNTeruyuki Nishimura
- Masato ChibaMCMasato Chiba
- Sumika OhyamaSOSumika Ohyama
- Riki Yoshida-YoshimiotoRYRiki Yoshida-Yoshimioto
- Kenji FujiiKFKenji Fujii
- Hideka HosakaHHHideka Hosaka
- Hiroko Goto-ShimazakiHGHiroko Goto-Shimazaki
- 1 December 2011
- journal article
- research article
- Published by Elsevier in Molecular Pharmacology
- Vol. 80 (6) , 1156-1165
Abstract
Glucokinase activators (GKAs) are small-molecule agents that enhance glucose sensing by pancreatic β cells and glucose metabolism by hepatocytes. There is strong interest in these agents as potential therapies for type 2 diabetes. Here, we report key pharmacokinetic and pharmacodynamic findings from preclinical studies of the GKA 3-[[6-(ethylsulfonyl)-3-pyridinyl]oxy]-5-[(1S)-2-hydroxy-1-methylethoxy]-N-(1-methyl-1H-pyrazol-3-yl)benzamide (MK-0941). Incubated in vitro with recombinant human glucokinase, 1 μM MK-0941 lowered the S0.5 of this enzyme for glucose from 6.9 to 1.4 mM and increased the maximum velocity of glucose phosphorylation by 1.5-fold. In 2.5 and 10 mM glucose, the EC50 values for activation of GK by MK-0941 were 0.240 and 0.065 μM, respectively. Treatment of isolated rat islets of Langerhans and hepatocytes with 10 μM MK-0941 increased insulin secretion by 17-fold and glucose uptake up to 18-fold, respectively. MK-0941 exhibited strong glucose-lowering activity in C57BL/6J mice maintained on a high-fat diet (HFD), db/db mice, HFD plus low-dose streptozotocin-treated mice, and nondiabetic dogs. In both mice and dogs, oral doses of MK-0941 were rapidly absorbed and rapidly cleared from the blood; plasma levels reached maximum within 1 h and fell thereafter with a half-life of ∼2 h. During oral glucose tolerance testing in dogs, MK-0941 reduced total area-under-the-curve postchallenge (0–2 h) plasma glucose levels by up to 48% compared with vehicle-treated controls. When administered twice daily to mice for 16 days, and once daily to the dog for 4 days, MK-0941 remained efficacious on successive days. These findings support further investigation of MK-0941 as a potential therapeutic agent for treatment of type 2 diabetes.Keywords
This publication has 33 references indexed in Scilit:
- Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 DiabetesDiabetes Care, 2011
- Garlic Accelerates Red Blood Cell Turnover and Splenic Erythropoietic Gene Expression in Mice: Evidence for Erythropoietin-Independent ErythropoiesisPLOS ONE, 2010
- Novel glucokinase activators: a patent review (2008 – 2010)Expert Opinion on Therapeutic Patents, 2010
- Glucokinase activators (GKAs) promise a new pharmacotherapy for diabeticsF1000 Medicine Reports, 2010
- Evaluation of a real-time, continuous monitor of glucose concentration in healthy dogs during anesthesiaAmerican Journal of Veterinary Research, 2010
- Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 DiabetesJournal of Medicinal Chemistry, 2009
- The Barrier of Hypoglycemia in DiabetesDiabetes, 2008
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 DiabetesDiabetes, 2006
- The Network of Glucokinase-Expressing Cells in Glucose Homeostasis and the Potential of Glucokinase Activators for Diabetes TherapyDiabetes, 2006